Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice-Reference-Cited by-同舟云学术

Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice

Published:2022-06 Issue:6 Volume:79 Page:
ISSN:1420-682X
Container-title:Cellular and Molecular Life Sciences
language:en
Short-container-title:Cell. Mol. Life Sci.

Author:

Noel Kathleen,Bokhari A.’dem,Bertrand Romane,Renaud Florence,Bourgoin Pierre,Cohen Romain,Svrcek Magali,Joly Anne-Christine,Duval Alex,Collura Ada^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00018-022-04293-3.pdf

Reference33 articles.

1. Svrcek M, Lascols O, Cohen R, Collura A, Jonchere V, Flejou JF, Buhard O, Duval A (2019) MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Bull Cancer 106:119–128. https://doi.org/10.1016/j.bulcan.2018.12.008

2. Dorard C, de Thonel A, Collura A et al (2011) Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med 17:1283–1289. https://doi.org/10.1038/nm.2457

3. Boudesco C, Verhoeyen E, Martin L et al (2018) HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood J Am Soc Hematol 132(5):510–520

4. Zappasodi R, Bongarzone I, Ghedini GC et al (2011) Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 118:4421–4430. https://doi.org/10.1182/blood-2011-06-364570

5. Chatterjee S, Burns TF (2017) Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci 18:1978. https://doi.org/10.3390/ijms18091978